Share on StockTwits

Mylan (NYSE:MYL) Director Neil F. Dimick sold 5,432 shares of Mylan stock in a transaction that occurred on Thursday, June 19th. The stock was sold at an average price of $50.81, for a total value of $275,999.92. Following the transaction, the director now directly owns 36,878 shares in the company, valued at approximately $1,873,771. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Mylan (NYSE:MYL) traded up 1.41% on Friday, hitting $51.12. 4,911,626 shares of the company’s stock traded hands. Mylan has a one year low of $29.93 and a one year high of $57.52. The stock has a 50-day moving average of $48.85 and a 200-day moving average of $47.84. The company has a market cap of $19.105 billion and a P/E ratio of 31.49. Mylan also was the target of some unusual options trading on Wednesday. Stock traders acquired 5,634 put options on the stock. This represents an increase of approximately 343% compared to the average volume of 1,273 put options.

Mylan (NYSE:MYL) last announced its earnings results on Thursday, May 1st. The company reported $0.66 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.68 by $0.02. The company had revenue of $1.72 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the company posted $0.62 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. On average, analysts predict that Mylan will post $3.40 earnings per share for the current fiscal year.

A number of research firms have recently commented on MYL. Analysts at Zacks reiterated a “neutral” rating on shares of Mylan in a research note on Wednesday. They now have a $53.00 price target on the stock. Separately, analysts at Wells Fargo & Co. initiated coverage on shares of Mylan in a research note on Wednesday, June 11th. They set an “outperform” rating on the stock. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $48.00.

Mylan Inc (NYSE:MYL) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.